Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Osteoclasts are multinucleated myeloid lineage cells formed in response to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) by fusion of bone marrow–derived precursors that circulate in the blood and are attracted to sites of bone resorption in response to factors, such as sphingosine-1 phosphate signaling. Major advances in understanding of the molecular mechanisms regulating osteoclast functions have been made in the past 20 years, mainly from mouse and human genetic studies. These have revealed that osteoclasts express and respond to proinflammatory and anti-inflammatory cytokines. Some of these cytokines activate NF-κB and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) signaling to induce osteoclast formation and activity and also regulate communication with neighboring cells through signaling proteins, including ephrins and semaphorins. Osteoclasts also positively and negatively regulate immune responses and osteoblastic bone formation. These advances have led to development of new inhibitors of bone resorption that are in clinical use or in clinical trials; and more should follow, based on these advances. This article reviews current understanding of how bone resorption is regulated both positively and negatively in normal and pathologic states. © 2013 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701 · cited 4×
“NFATc1 is also activated through PLCg by costimulatory signaling, which is initiated by ligand binding to immunoglobulin (Ig)‐like receptors, such as triggering receptor expressed in myeloid cells‐2 (TREM‐2) and osteoclast‐ associated receptor (OSCAR).((34)) These receptors are expressed on OCPs and they recruit adapt…”
BackgroundInfluentialOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287 · cited 1×
“Lining cells communicate with osteocytes within the bone and with osteoblastic cells in the marrow through their extensive dendritic processes, which could mediate signaling that leads to the cytoplasmic retraction,((73)) but the mechanisms involved remain unknown.”
BackgroundTranscriptional regulation by calcium, calcineurin, and NFAT
Hogan, P. G., Chen, L., Nardone, J., & Rao, A. (2003) · Genes & Development · doi:10.1101/gad.1102703 · Cited by 1,991 · cited 1×
“NFAT transcription factors regulate immune responses as well as cardiovascular, muscle, and neuronal and other cell functions.((42))”
BackgroundOsteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878 · cited 5×
“It promotes expression of RANK on OCP cell membranes, leaving the RANKþ cells primed to respond to RANKL.”
BackgroundResultInfluentialFunctions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · cited 3×
“Osteoprotegerin (OPG) is the major negative regulator of bone resorption.((26,27)) OPG is secreted by osteoblastic and other cell types and binds to RANKL as a decoy receptor, thus preventing its interaction with RANK.”
BackgroundSelf-citationEvidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts
Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.025 · Cited by 1,013
Requirement for NF-κB in osteoclast and B-cell development
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes & Development · doi:10.1101/gad.11.24.3482 · Cited by 996
Self-citationDC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050645 · Cited by 890
Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., & Ikeda, K. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.001 · Cited by 848
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., & Boyce, B. F. (1996) · Nature Medicine · doi:10.1038/nm1096-1132 · Cited by 813 · cited 1×
“One of the earliest reports of OC apoptosis was in response to estrogen and was mediated by increased expression of TGFb by bone marrow cells.((117)) Estrogen also induces OC apoptosis by increasing Fas‐ligand expression in OCs,((118)) and estrogen receptor alpha signaling also inhibits expression of genes regulating…”
BackgroundSelf-citationBidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Osteoprotection by semaphorin 3A
Hayashi, M., Nakashima, T., Taniguchi, M., Kodama, T., Kumanogoh, A., & Takayanagi, H. (2012) · Nature · doi:10.1038/nature11000 · Cited by 606 · cited 2×
“Importantly, treatment of mice with Sema3A inhibited bone resorption and increased bone formation in normal mice and enhanced bone regeneration in a mouse cortical bone defect model.((110)) Sema4D is membrane‐bound and binds to plexin1 on target cells.”
BackgroundMaeda, K., Kobayashi, Y., Udagawa, N., Uehara, S., Ishihara, A., Mizoguchi, T., Kikuchi, Y., Takada, I., Kato, S., Kani, S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2653 · Cited by 542 · cited 6×
“This is a potentially important target for therapeutic intervention because a soluble form of Ror2 acted as a decoy receptor of Wnt5a and prevented bone destruction in mouse models of arthritis.((97)) In addition, Jagged1/Notch1 signaling, which regulates the number of mesenchymal stem cells (MSCs) and osteoblast diff…”
BackgroundInfluentialAutophagy Proteins Regulate the Secretory Component of Osteoclastic Bone Resorption
DeSelm, C. J., Miller, B. C., Zou, W., Beatty, W. L., van Meel, E., Takahata, Y., Klumperman, J., Tooze, S. A., Teitelbaum, S. L., & Virgin, H. W. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.08.016 · Cited by 487 · cited 1×
“Vesicle fusion is promoted by the small GTPase Ras‐associated protein RAB7 (Rab7) and synaptotagmin VII, a calcium‐sensing molecule, and by proteins involved in autophagy and extracellular protein secretion, including Autophagy 5 (Atg5), Atg7, Atg4B, and light chain 3 (LC3).((80,81)) Accordingly, synaptotagmin VII / o…”
BackgroundExpanding TRAF function: TRAF3 as a tri-faced immune regulator
Häcker, H., Tseng, P.-H., & Karin, M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2998 · Cited by 471
Semaphorins and their receptors in immune cell interactions
Suzuki, K., Kumanogoh, A., & Kikutani, H. (2008) · Nature Immunology · doi:10.1038/ni1553 · Cited by 400
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Jia, D., O’Brien, C. A., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2006) · Endocrinology · doi:10.1210/en.2006-0459 · Cited by 394
Semaphorin Regulation of Cellular Morphology
Tran, T. S., Kolodkin, A. L., & Bharadwaj, R. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093554 · Cited by 388
A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone
Andersen, T. L., Sondergaard, T. E., Skorzynska, K. E., Dagnaes-Hansen, F., Plesner, T. L., Hauge, E. M., Plesner, T., & Delaisse, J.-M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080627 · Cited by 325 · cited 1×
“Morphologic studies have identified a thin canopy of connective tissue covering resorption sites, and small vessels pass through it into BRUs, bringing cells and nutrients.((67))”
BackgroundHuman Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations
Guerrini, M. M., Sobacchi, C., Cassani, B., Abinun, M., Kilic, S. S., Pangrazio, A., Moratto, D., Mazzolari, E., Clayton-Smith, J., Orchard, P., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.015 · Cited by 309 · cited 1×
“Kindreds with RANKL or RANK deletion mutations have marked osteopetrosis and appear to lack palpable lymph nodes.((62,63))”
BackgroundLi, P., Schwarz, E. M., O'Keefe, R. J., Ma, L., Boyce, B. F., & Xing, L. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301233 · Cited by 220
Self-citationMechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics
VAANANEN, K. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.018 · Cited by 176 · cited 2×
“induce OC apoptosis, but other antiresorptive drugs, including calcitonin((68)) and the cathepsin K inhibitors odanacatib and ONO‐5334, which are in phase 3 clinical trials, do not.”
BackgroundXing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F., & Boyce, B. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1200 · Cited by 165
Self-citationZhao, B., & Ivashkiv, L. B. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3379 · Cited by 144
Crockett, J. C., Mellis, D. J., Scott, D. I., & Helfrich, M. H. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1272-8 · Cited by 143 · cited 1×
“Activating mutations in the RANK gene are responsible for a number of rare bone diseases, including familial expansile osteolysis, and expansile skeletal hyperphosphatasia,((65)) in which there is increased localized, rather than generalized OC formation and bone resorption.”
BackgroundRole of T cells in ovariectomy induced bone loss—revisited
Pacifici, R. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1500 · Cited by 142 · cited 5×
“RANKL is a member of the tumor necrosis factor (TNF) superfamily of proteins and is expressed by osteoblast lineage and other cell types, including T and B lymphocytes.((15)) In the absence of essential molecules that signal downstream of RANK, such as NF‐kB and c‐Fos, increased numbers of CD11bþ OCPs accumulate (as i…”
BackgroundResultInfluential
Cited by
Osteoblast–osteoclast interactions
Chen, X., Wang, Z., Duan, N., Zhu, G., Schwarz, E. M., & Xie, C. (2018) · Connective Tissue Research · doi:10.1080/03008207.2017.1290085 · Cited by 873
Advances in the regulation of osteoclasts and osteoclast functions
Boyce, B. F. (2013) · Journal of Dental Research · doi:10.1177/0022034513500306 · Cited by 457
Self-citationOsteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption
McDonald, M. M., Khoo, W. H., Ng, P. Y., Xiao, Y., Zamerli, J., Thatcher, P., Kyaw, W., Pathmanandavel, K., Grootveld, A. K., Moran, I., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.002 · Cited by 433
The role of cytokines in inflammatory bone loss
Souza, P. P. C., & Lerner, U. H. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.822766 · Cited by 269
Adult Stem Cells for Bone Regeneration and Repair
Iaquinta, M. R., Mazzoni, E., Bononi, I., Rotondo, J. C., Mazziotta, C., Montesi, M., Sprio, S., Tampieri, A., Tognon, M., & Martini, F. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00268 · Cited by 259
Metadata
- Authors
- Boyce, B. F.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-21
- Volume
- 28
- Issue
- 4
- Pages
- 711-722
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1971384336
- Cited by
- 149
- References
- 33
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.